NewsBite

Cochlear

Advertisement
Mike Cannon Brookes at Director conference at AICD Climate Governance Forum, at Sydney Hilton Hotel on Aug 11, 2023. Photo: Flavio Brancaleone / AFR

The hundreds of millions in tax incentives for Australian start-ups that went south

The R&D tax offset has served as a life raft for some of Australia’s most prominent technology start-ups, though in some cases it wasn’t enough.

  • David Swan

Latest

Australian research has led to a number of highly-significant medical innovations.

Our track record in medical innovation can only be maintained with funding support

Australian researchers are responsible for a series of globally significant medical inventions and innovations.

  • The Herald's View
Wall Street has had a mixed start to the week.

Healthcare companies, wage data lift ASX after Wall Street gain

The Australian sharemarket climbed on the back of healthcare companies after a set of strong results from some of its biggest players and softer wage data.

  • Millie Muroi
Cochlear CEO Dig Howitt said...

‘Certainly pleased’: Cochlear, CSL count win on multinational tax reporting

Corporate Australia has warned against new tax rules that would require them to share new levels of global tax information publicly.

  • Emma Koehn
Cochlear CEO and president Dig Howitt.

Investing in workers critical to solving healthcare squeeze, says Cochlear boss

Cochlear chief executive Dig Howitt says Australia needs training and immigration policies that allow skilled workers to flow into the healthcare sector.

  • Emma Koehn
Cochlear has asked for a jury trial to resolve the dispute.

‘Baseless’: Australian biotech Cochlear steps up fight against US university over hearing device

Hearing implant maker Cochlear will bring a counter claim against the University of Pittsburgh, which has accused the company of infringing on one of its patents with its Nucleus 7 hearing device.

  • Emma Koehn
Advertisement
Cochlear CEO Dig Howitt said the company expects hospitals to "proceed cautiously" with the resumption of elective surgery.

Cochlear boss urges investment in healthcare workers

Revenues were up at the hearing implants maker but unit volumes in its developed markets dipped as the impact of the Delta and Omicron variants saw operating theatres running below capacity.

  • Emma Koehn
“I’ve never felt like I haven’t been able to provide the time and energy to the CEOs, executives and boards of both companies,” says Qantas and Woodside chairman Richard Goyder.

Board games: Is a cosy directors’ club a risk to corporate Australia?

A small group of powerful men, and increasingly women, dominate the boards of Australia’s biggest companies. And some fear the group is too small.

  • Anne Hyland
Cochlear CEO Dig Howitt says implant unit sales were down 80 per cent in April.

Rapid testing no substitute to COVID vaccination: Cochlear boss

The $17 billion hearing implants maker has returned to profit, with its boss focused on emerging from the pandemic with a stronger market share. But the Delta variant could threaten its earnings forecast.

  • Emma Koehn
CEO of Cochlear, Dig Howitt, said Australia should consider more incentives for companies to create more locally-produced patents and IP.

Vaccine ‘not a panacea’ as surgeries bounce back: Cochlear boss

The hearing implant maker is still on the long path back to a COVID normal but can see some light at the end of the tunnel.

  • Emma Koehn

Original URL: https://www.theage.com.au/topic/coh-ej